Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients

Abdalla, 1986, Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients, Clinical Chemistry, 32, 805, 10.1093/clinchem/32.5.805 Adler, 1993, Vitamin E treatment of tardive dyskinesia, American Journal of Psychiatry, 150, 1405, 10.1176/ajp.150.9.1405 Aebi, 1984, Catalase in vitro, 3, 277 Akyol, 2002, The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the role of oxidant/antioxidant imbalance, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 995, 10.1016/S0278-5846(02)00220-8 1994 Andreasen, 1982, Negative vs. positive schizophrenia: definition and validation, Archives of General Psychiatry, 39, 789, 10.1001/archpsyc.1982.04290070025006 Angst, 2002, Historical aspects of the dichotomy between manic-depressive disorders and schizophrenia, Schizophrenia Research, 57, 5, 10.1016/S0920-9964(02)00328-6 Arvindakshan, M., 2003. Ph.D. Thesis: The Role of Membrane Essential Polyunsaturated Fatty Acids in Schizophrenia Outcome. Pune University Press, Pune, India Arvindakshan, 2003, Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia, Schizophrenia Research, 62, 195, 10.1016/S0920-9964(02)00284-0 Arvindakshan, 2003, Membrane essential polyunsaturated fatty acids (EPUFA) and schizophrenia outcome: EPUFA and lipid peroxide levels in never-medicated and medicated schizophrenics, Biological Psychiatry, 53, 56, 10.1016/S0006-3223(02)01443-9 Cadet, 1987, Free radicals and the developmental pathophysiology of schizophrenic burnout, Integrative Psychiatry, 5, 40 Cadet, 1990, Chronic treatment with prolixin causes oxidative stress in rat brain, Biological Psychiatry, 28, 738, 10.1016/0006-3223(90)90461-A Carpenter, 1988, Deficit and non-deficit forms of schizophrenia: the concept, American Journal of Psychiatry, 145, 578, 10.1176/ajp.145.5.578 Christensen, 1988, Fat consumption and schizophrenia, Acta Psychiatrica Scandinavica, 78, 587, 10.1111/j.1600-0447.1988.tb06388.x Crow, 1985, The two-syndrome concept: origins and current status, Schizophrenia Bulletin, 11, 471, 10.1093/schbul/11.3.471 Crow, 1990, The continuum of psychosis and its genetic origins: the sixty-fifth Maudsley Lecture, British Journal of Psychiatry, 156, 788, 10.1192/bjp.156.6.788 Crow, 1995, Psychotic continuum or disease entities? The critical impact of nosology on the problem of etiology, 151 Edwards, R.W., Peet, M., 1999. Essential fatty acid intake in relation to depression. In: Peet, M., Glen, I., Horrobin, D.F. (Eds.), Phospholipid Spectrum Disorders in Psychiatry. Marius Press, Lancashire, UK Evans, D.R., Parikh, V.V., Khan, M.M., Coussons, C., Buckley, P.F., Mahadik, S.P., 2003. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, in press Fenton, 2000, Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia, Biological Psychiatry, 47, 8, 10.1016/S0006-3223(99)00092-X Gershon, 1988, A controlled family study of chronic psychosis, Archives of General Psychiatry, 45, 328, 10.1001/archpsyc.1988.01800280038006 Glen, 1994, A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases, Schizophrenia Research, 12, 53, 10.1016/0920-9964(94)90084-1 Horrobin, 1994, The membrane hypothesis of schizophrenia, Schizophrenia Research, 13, 195, 10.1016/0920-9964(94)90043-4 Horrobin, 1998, The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia, Schizophrenia Research, 30, 193, 10.1016/S0920-9964(97)00151-5 Jablensky, 1986, Epidemiology of schizophrenia: a European perspective, Schizophrenia Bulletin, 12, 52, 10.1093/schbul/12.1.52 Jablensky, 1986, Schizophrenia and social adjustment. A prospective longitudinal study, Monogr Gesamtgeb Psychiatr Psychiatry Series, 40, 1 Jablensky, 1991, Schizophrenia: manifestations, incidence and course in different cultures, Psychological Medicine and Monographs Supplement, 20, 1, 10.1017/S0264180100000904 Jeding, 1995, Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs, Biochemical Pharmacology, 49, 359, 10.1016/0006-2952(94)00424-K Kahlbaum, K., 1963. Die Gruppirung der Psychischen Krankheiten und die Eintheilung der Seelenstorungen. AW Kafemann, Danzing Kay, 1987, The Positive and Negative Syndrome Scale (PANSS) for schizophrenia, Schizophrenia Bulletin, 13, 261, 10.1093/schbul/13.2.261 Khan, 2001, Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database, American Journal of Psychiatry, 158, 1449, 10.1176/appi.ajp.158.9.1449 Khan, 2002, Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics, Schizophrenia Research, 58, 1, 10.1016/S0920-9964(01)00334-6 Kirkpatrick, 1993, Case identification and stability of the deficit syndrome of schizophrenia, Psychiatry Research, 47, 47, 10.1016/0165-1781(93)90054-K Kraepelin, E., 1899. Psychiatrie. Ein Lehrbuch fur Studierende und Arzte, 6th ed. Johann Ambrocius Barth, Leipzig Kuloglu, 2002, Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder, Cell Biochemistry and Function, 20, 171, 10.1002/cbf.940 Leff, 1992, The International Pilot Study of Schizophrenia: five-year follow-up findings, Psychological Medicine, 22, 131, 10.1017/S0033291700032797 Lohr, 1988, Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms, Schizophrenia Bulletin, 14, 291, 10.1093/schbul/14.2.291 Lohr, 1990, Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia, Biological Psychiatry, 28, 535, 10.1016/0006-3223(90)90490-S Maes, 1999, Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients, Psychiatric Research, 85, 275, 10.1016/S0165-1781(99)00014-1 Mahadik, 1997, Essential fatty acids in the treatment of schizophrenia, Drugs of Today, 33, 5 Mahadik, 2001, Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia, Progress in Neuropsychopharmacology and Biological Psychiatry, 25, 463, 10.1016/S0278-5846(00)00181-0 Mahadik, 1996, Antioxidants in the treatment of schizophrenia, Drugs of Today, 32, 553 Mahadik, 1996, Free radical pathology and antioxidant defense in schizophrenia: a review, Schizophrenia Research, 19, 1, 10.1016/0920-9964(95)00049-6 Mahadik, 1996, Oxidative injury and potential use of antioxidants in schizophrenia, Prostaglandins, Leukotrienes and Essential Fatty Acids, 55, 45, 10.1016/S0952-3278(96)90144-1 Mahadik, 1996, Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal controls, Psychiatry Research, 63, 133, 10.1016/0165-1781(96)02899-5 Mahadik, 1996, Utilization of precursor essential fatty acids in culture by skin fibroblasts from schizophrenic patients and normal controls, Prostaglandins, Leukotrienes and Essential Fatty Acids, 55, 65, 10.1016/S0952-3278(96)90147-7 Mahadik, 1998, Elevated plasma lipid peroxides at the onset of non-affective psychosis, Biological Psychiatry, 43, 674, 10.1016/S0006-3223(97)00282-5 Mahadik, 1999, Cultural and socio–economic differences in dietary intake of essential fatty acids and antioxidants: effects on the course and outcome of schizophrenia, 167 Mahadik, 1999, Membrane peroxidation and the neuropathology of schizophrenia, 99 Maier, 1993, Continuity and discontinuity of affective disorders and schizophrenia: results of a controlled family study, Archives of General Psychiatry, 50, 871, 10.1001/archpsyc.1993.01820230041004 McCreadie, 1995, The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia and in normal subjects, British Journal of Psychiatry, 170, 1 Mukherjee, 1996, Impaired antioxidant defense at the onset of psychosis, Schizophrenia Research, 19, 19, 10.1016/0920-9964(95)00048-8 Nemets, 2002, Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder, American Journal of Psychiatry, 159, 477, 10.1176/appi.ajp.159.3.477 Ohkawa, 1979, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction, Analytical Biochemistry, 95, 351, 10.1016/0003-2697(79)90738-3 Overall, 1962, Brief Psychiatric Rating Scale, Psychological Reports, 10, 799, 10.2466/pr0.1962.10.3.799 Parikh, 2002, Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain, Journal of Psychiatric Research, 37, 43, 10.1016/S0022-3956(02)00048-1 Peet, 2002, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms, Journal of Psychiatric Research, 36, 7, 10.1016/S0022-3956(01)00048-6 Peet, M., Glen, I., Horrobin, D.F. (Eds), 1999. Phospholipid Spectrum Disorders in Psychiatry. Marius Press Lancashire, UK Peet, 1993, Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment, International Clinical Psychopharmacology, 8, 151, 10.1097/00004850-199300830-00003 Ramchand, 1996, Reduced susceptibility to oxidative damage of erythrocyte membranes from medicated schizophrenic patients, Prostaglandins, Leukotrienes and Essential Fatty Acids, 55, 27, 10.1016/S0952-3278(96)90142-8 Reddy, 1991, Enzymes of the antioxidant defense system in chronic schizophrenic patients, Biological Psychiatry, 30, 409, 10.1016/0006-3223(91)90298-Z Reddy, 1996, Free radical pathology in schizophrenia: a review, Prostaglandins, Leukotrienes and Essential Fatty Acids, 55, 33, 10.1016/S0952-3278(96)90143-X Roy, 1984, Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain, Journal of Neurochemistry, 42, 628, 10.1111/j.1471-4159.1984.tb02728.x Simopoulos, 1991, Omega-3 fatty acids in health and disease and in growth and development, American Journal of Clinical Nutrition, 54, 438, 10.1093/ajcn/54.3.438 Smythies, 1997, Oxidative reactions and schizophrenia: a review-discussion, Schizophrenia Research, 24, 357, 10.1016/S0920-9964(97)00005-4 Stoklasova, 1990, Activities of blood glutathione peroxidase in schizophrenic and depressive patients, Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove, 33, 501 Stoll, 1999, Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial, Archives of General Psychiatry, 56, 407, 10.1001/archpsyc.56.5.407 Subramanyam, 1991, Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol, Biochemical and Biophysical Research Communications, 181, 573, 10.1016/0006-291X(91)91228-5 Taylor, 1992, Are schizophrenia and affective disorder related? A selective literature review, American Journal of Psychiatry, 149, 22, 10.1176/ajp.149.1.22 Wainwright, 1992, Do essential fatty acids play a role in brain and behavioral development?, Neuroscience and Biobehavioral Reviews, 16, 193, 10.1016/S0149-7634(05)80180-0 Williams, 1988, A structured interview guide for the Hamilton Depression Rating Scale, Archives of General Psychiatry, 45, 742, 10.1001/archpsyc.1988.01800320058007 Yao, 1998, Effects of haloperidol on antioxidant defense system enzymes in schizophrenia, Journal of Psychiatric Research, 32, 385, 10.1016/S0022-3956(98)00028-4 Yao, 2000, Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients, Schizophrenia Research, 42, 7, 10.1016/S0920-9964(99)00095-X Yao, 2001, Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications, CNS Drugs, 15, 287, 10.2165/00023210-200115040-00004